Study identifier:AZD1222 (ChAdOx1 nCoV-19)
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Results from four AZD1222 (ChAdOx1 nCoV-19) vaccine trials for COVID-19
COVID-19 disease
-
-
-
-
-
-
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2021
-
-
This study record has been created to publish the Plain Language Summary of the Lancet journal article focusing on results of 4 trials of the AZD1222 vaccine used to prevent COVID-19 disease caused by the SARS-CoV-2 virus. These clinical trials were sponsored by the University of Oxford with AstraZeneca as a collaborator. The purpose of this Plain Language Summary is to help you understand these results. University of Oxford and AstraZeneca jointly provided the Plain Language Summary. Go to Attachments tab to download the Plain Language Summary of the Lancet article.
No locations available
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.